See more : Beacon Roofing Supply, Inc. (BECN) Income Statement Analysis – Financial Results
Complete financial analysis of GT Biopharma, Inc. (GTBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GT Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- TILT Holdings Inc. (TILT.NE) Income Statement Analysis – Financial Results
- Lipum AB (publ) (LIPUM.ST) Income Statement Analysis – Financial Results
- Kuboo, Inc. (SGTB) Income Statement Analysis – Financial Results
- 4Front Ventures Corp. (FFVWF) Income Statement Analysis – Financial Results
- Lubelski Wegiel Bogdanka S.A. (LWB.WA) Income Statement Analysis – Financial Results
GT Biopharma, Inc. (GTBP)
About GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 | 1984 | 1983 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.00K | 61.00K | 368.00K | 342.00K | 26.00K | 11.00K | 48.00K | 1.14M | 6.05M | 5.78M | 2.50M | 2.36M | 2.74M | 2.05M | 2.97M | 3.54M | 7.17M | 5.10M | 5.10M | 4.90M | 5.10M | 3.50M | 3.00M | 2.80M | 2.70M | 4.80M | 5.10M | 3.20M | 2.30M | 3.00M | 2.40M | 4.16M | 3.83M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 7.00K | 2.00K | 1.00K | 2.00K | 57.00K | 226.00K | 94.00K | 48.00K | 65.00K | 50.00K | 909.00K | 3.26M | 3.08M | 1.35M | 1.22M | 1.50M | 1.14M | 2.43M | 2.62M | 5.05M | 2.60M | 2.00M | 1.60M | 1.60M | 1.50M | 1.20M | 1.20M | 1.00M | 1.90M | 2.10M | 1.20M | 500.00K | 1.10M | 900.00K | 2.33M | 2.28M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -4.00K | -7.00K | -2.00K | -1.00K | 25.00K | 4.00K | 142.00K | 248.00K | -22.00K | -54.00K | -2.00K | 234.00K | 2.79M | 2.69M | 1.15M | 1.15M | 1.24M | 910.00K | 538.00K | 924.00K | 2.11M | 2.50M | 3.10M | 3.30M | 3.50M | 2.00M | 1.80M | 1.60M | 1.70M | 2.90M | 3.00M | 2.00M | 1.80M | 1.90M | 1.50M | 1.83M | 1.55M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 92.59% | 6.56% | 38.59% | 72.51% | -84.62% | -490.91% | -4.17% | 20.47% | 46.09% | 46.61% | 46.14% | 48.56% | 45.40% | 44.39% | 18.13% | 26.10% | 29.50% | 49.02% | 60.78% | 67.35% | 68.63% | 57.14% | 60.00% | 57.14% | 62.96% | 60.42% | 58.82% | 62.50% | 78.26% | 63.33% | 62.50% | 43.99% | 40.47% |
| Research & Development | 6.47M | 8.81M | 9.59M | 485.00K | 1.67M | 9.07M | 1.07M | 975.00K | 1.00M | 0.00 | 0.00 | 0.00 | 17.00K | 179.00K | 0.00 | 44.00K | 1.04M | 708.00K | 499.00K | 236.00K | 369.00K | 463.00K | 762.00K | 1.91M | 2.40M | 4.40M | 4.30M | 4.90M | 4.30M | 1.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 590.00K | 400.00K |
| General & Administrative | 0.00 | 0.00 | 47.92M | 6.28M | 9.79M | 12.49M | 0.00 | 0.00 | 0.00 | 0.00 | 935.00K | 3.36M | 3.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.13M | 1.19M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 400.00K | 420.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.11M | 12.45M | 47.92M | 6.28M | 9.79M | 12.49M | 134.50M | 8.40M | 7.95M | 2.40M | 935.00K | 3.76M | 3.89M | 2.26M | 1.15M | 1.40M | 2.87M | 4.65M | 2.34M | 2.03M | 1.65M | 1.26M | 2.29M | 3.30M | 3.29M | 3.60M | 2.60M | 2.80M | 3.30M | 1.70M | 3.40M | 2.10M | 2.20M | 2.40M | 2.50M | 2.10M | 1.60M | 2.50M | 2.30M | 1.13M | 1.19M |
| Other Expenses | 0.00 | 0.00 | -242.76K | -12.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 155.00K | 0.00 | 0.00 | 0.00 | 942.00K | 443.00K | 838.00K | 1.60M | 1.20M | 1.40M | 1.40M | 600.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K |
| Operating Expenses | 13.58M | 21.26M | 57.52M | 6.76M | 11.46M | 21.55M | 135.57M | 9.37M | 8.95M | 2.40M | 935.00K | 3.76M | 3.91M | 2.44M | 1.15M | 1.45M | 3.90M | 5.36M | 2.84M | 2.26M | 2.02M | 1.72M | 3.99M | 5.65M | 6.52M | 9.60M | 8.10M | 9.10M | 9.00M | 4.00M | 3.50M | 2.10M | 2.20M | 2.40M | 2.50M | 2.10M | 1.60M | 2.50M | 2.30M | 1.72M | 1.60M |
| Cost & Expenses | 13.58M | 21.26M | 57.52M | 6.76M | 11.46M | 21.55M | 135.57M | 9.37M | 8.95M | 2.46M | 1.16M | 3.86M | 3.95M | 2.51M | 1.20M | 2.35M | 7.17M | 8.45M | 4.19M | 3.48M | 3.51M | 2.86M | 6.42M | 8.27M | 11.58M | 12.20M | 10.10M | 10.70M | 10.60M | 5.50M | 4.70M | 3.30M | 3.20M | 4.30M | 4.60M | 3.30M | 2.10M | 3.60M | 3.20M | 4.05M | 3.88M |
| Interest Income | 567.00K | 292.00K | 38.00K | 3.32K | 2.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 0.00 | 52.00K | 80.00K | 110.00K | 1.00K | 1.00K | 7.00K | 29.00K | 180.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 8.00K | 718.00K | 3.32M | 2.13M | 9.12M | 8.60M | 6.56M | 17.04M | 5.15M | 1.20M | 1.65M | 556.00K | 513.00K | 1.14M | 1.66M | 1.01M | 2.16M | 26.00K | 101.00K | 14.00K | 18.00K | 14.00K | 90.00K | 0.00 | 300.00K | 0.00 | 100.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 290.00K | 210.00K |
| Depreciation & Amortization | 13.58M | 21.26M | 57.52M | 4.00K | 4.00K | 7.00K | 2.00K | 1.00K | 2.00K | 22.00K | 2.00K | 3.00K | 23.00K | 31.00K | 55.00K | 251.00K | 893.00K | 301.00K | 154.00K | 785.00K | 177.00K | 282.00K | 412.00K | 443.00K | 838.00K | 1.60M | 1.20M | 1.40M | 1.40M | 600.00K | 100.00K | -300.00K | -300.00K | -300.00K | -300.00K | -200.00K | 100.00K | -200.00K | -300.00K | 790.00K | 480.00K |
| EBITDA | 5.98M | 0.00 | 0.00 | -24.98M | -11.45M | -250.06M | -135.57M | -9.37M | -8.93M | -2.37M | -791.00K | -3.61M | -3.12M | -2.45M | -1.06M | -822.00K | -223.00K | -2.37M | -1.54M | -1.72M | -596.00K | -529.00K | -3.04M | -4.28M | -3.57M | -5.50M | -3.80M | -4.50M | -4.10M | -1.40M | -1.60M | -800.00K | -800.00K | 200.00K | 200.00K | -300.00K | 200.00K | -800.00K | -1.10M | 890.00K | 430.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33,055.56% | -3,891.80% | -602.17% | -1,026.61% | -15,019.23% | -22,418.18% | -2,285.42% | -83.99% | -48.64% | -42.64% | -1.56% | 47.08% | -22.04% | -25.80% | -68.80% | -120.99% | -50.65% | -113.73% | -76.47% | -89.80% | -15.69% | 62.86% | -60.00% | -28.57% | -29.63% | 4.17% | 3.92% | -9.38% | 13.04% | -26.67% | -45.83% | 21.39% | 11.23% |
| Operating Income | -13.58M | -21.26M | -57.52M | -6.76M | -16.06M | -250.07M | -135.57M | -9.37M | -8.93M | -2.40M | -793.00K | -3.51M | -3.93M | -2.50M | -1.16M | -1.21M | -1.12M | -2.67M | -3.19M | -1.72M | -773.00K | -811.00K | -3.45M | -4.73M | -4.41M | -7.10M | -5.00M | -5.80M | -5.50M | -2.00M | -1.70M | -500.00K | -500.00K | 500.00K | 500.00K | -100.00K | 200.00K | -600.00K | -800.00K | 100.00K | -50.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33,062.96% | -3,927.87% | -215.49% | -1,027.49% | -15,107.69% | -22,700.00% | -2,408.33% | -105.95% | -18.45% | -46.23% | -127.71% | -72.72% | -28.21% | -39.56% | -116.34% | -133.50% | -61.55% | -139.22% | -98.04% | -118.37% | -107.84% | -57.14% | -56.67% | -17.86% | -18.52% | 10.42% | 9.80% | -3.13% | 8.70% | -20.00% | -33.33% | 2.40% | -1.31% |
| Total Other Income/Expenses | 5.98M | 373.00K | -498.00K | -21.53M | -22.59M | -9.12M | -7.68M | 19.14M | -12.53M | -21.11M | 229.00K | -1.75M | 228.00K | -498.00K | -1.09M | -1.50M | 1.49M | -1.98M | 82.00K | -937.00K | -5.00K | -11.00K | -999.00K | 0.00 | 57.00K | 300.00K | 100.00K | 0.00 | -3.30M | -3.60M | 200.00K | 300.00K | 300.00K | 300.00K | 300.00K | 200.00K | 200.00K | 200.00K | 300.00K | 290.00K | 210.00K |
| Income Before Tax | -7.60M | -20.88M | -58.01M | -28.30M | -38.65M | -259.19M | -143.25M | 21.03M | -32.73M | -23.49M | -564.00K | -5.26M | -3.70M | -3.00M | -2.25M | -2.71M | 546.00K | 4.82M | -3.11M | -2.66M | -778.00K | -822.00K | -4.45M | 0.00 | -4.35M | -6.80M | -4.90M | 0.00 | -8.80M | -5.60M | -1.50M | -200.00K | -200.00K | 800.00K | 800.00K | 100.00K | 400.00K | -400.00K | -500.00K | 390.00K | 160.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -121,207.41% | -38,506.56% | -153.26% | -1,538.30% | -14,230.77% | -27,227.27% | -4,679.17% | -237.01% | 9.03% | 83.45% | -124.43% | -112.35% | -28.39% | -40.10% | -150.00% | 0.00% | -60.75% | -133.33% | -96.08% | 0.00% | -172.55% | -160.00% | -50.00% | -7.14% | -7.41% | 16.67% | 15.69% | 3.13% | 17.39% | -13.33% | -20.83% | 9.38% | 4.18% |
| Income Tax Expense | 0.00 | -381.00K | 680.00K | 3.32M | 2.13M | -228.52M | 7.68M | -30.41M | 17.04M | 5.15M | -292.00K | 1.56M | 556.00K | 513.00K | 1.14M | 77.00K | 75.00K | 120.00K | 2.00K | 1.54M | 13.00K | 0.00 | 42.00K | -42.00K | 85.00K | 0.00 | 200.00K | 200.00K | 3.40M | 3.60M | -200.00K | 100.00K | 0.00 | -100.00K | 100.00K | 0.00 | 100.00K | 0.00 | -200.00K | 180.00K | 70.00K |
| Net Income | -7.60M | -20.50M | -58.69M | -31.62M | -40.78M | -259.19M | -143.25M | 21.03M | -32.73M | -23.49M | -501.00K | -5.17M | -3.70M | -3.00M | -2.25M | -5.01M | 471.00K | -4.94M | -3.11M | -2.66M | -791.00K | -822.00K | -3.50M | -4.68M | -4.50M | -7.10M | -5.20M | -6.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 900.00K | 700.00K | 100.00K | 300.00K | -400.00K | -300.00K | 420.00K | 150.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -121,207.41% | -38,506.56% | -136.14% | -1,511.99% | -14,230.77% | -27,227.27% | -4,679.17% | -437.97% | 7.79% | -85.53% | -124.51% | -112.35% | -28.87% | -40.10% | -117.76% | -132.32% | -62.74% | -139.22% | -101.96% | -122.45% | -174.51% | -160.00% | -50.00% | -10.71% | -7.41% | 18.75% | 13.73% | 3.13% | 13.04% | -13.33% | -12.50% | 10.10% | 3.92% |
| EPS | -5.64 | -19.30 | -62.54 | -216.29 | -361.49 | -87.70 | -145.22 | 4.39K | -69.63K | -50.62K | -1.12K | -13.19K | -17.54K | -25.60K | -43.19K | -139.06K | 13.08K | -145.29K | -94.21K | -83.00K | -39.55K | -117.43K | -499.29K | -669.14K | -749.17K | -1.18M | -1.30M | -3.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 1.08M | 956.34K | 191.27K | 382.54K | -400.00K | -300.00K | 0.01 | 0.00 |
| EPS Diluted | -5.64 | -19.30 | -62.54 | -216.29 | -361.49 | -87.70 | -145.22 | 4.39K | -69.63K | -50.62K | -1.12K | -13.19K | -17.54K | -25.60K | -43.19K | -139.06K | 13.08K | -145.29K | -94.21K | -83.00K | -39.55K | -117.43K | -499.29K | -669.14K | -749.17K | -1.18M | -1.30M | -3.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 1.08M | 956.34K | 191.27K | 382.54K | -400.00K | -300.00K | 0.01 | 0.00 |
| Weighted Avg Shares Out | 1.35M | 1.06M | 938.52K | 146.17K | 112.80K | 2.96M | 986.42K | 4.79K | 470.00 | 464.00 | 449.00 | 392.00 | 211.00 | 117.00 | 52.00 | 36.00 | 36.00 | 34.00 | 33.00 | 32.00 | 20.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 30.58M | 30.58M |
| Weighted Avg Shares Out (Dil) | 1.35M | 1.06M | 938.52K | 146.17K | 112.80K | 2.96M | 986.42K | 4.79K | 470.00 | 464.00 | 449.00 | 392.00 | 211.00 | 117.00 | 52.00 | 36.00 | 36.00 | 34.00 | 33.00 | 32.00 | 20.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 30.58M | 30.58M |
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders
BRISBANE, California, Dec. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (Nasdaq: GTBP) (the “Company”), announced that the two leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended GT Biopharma...
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced the submission of...
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
BRISBANE, CALIFORNIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced positive preclinical data...
GT Biopharma Reports Third Quarter 2023 Financial Results
BRISBANE, CALIFORNIA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced third...
GT Biopharma, Inc. (GTBP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the...
GT Biopharma Reports Second Quarter 2023 Financial Results
C ash of approximately $ 1 8.0 million as of June 30 , 202 3 , provide s ample runway to fund operations into Q 3 202 4; anticipated to b e sufficient to achieve IND clearance for GTB-3650 and...
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023
BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Dr. Jeffrey...
Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now
GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the...
All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy
GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Dr. Jeffrey...
Source: https://incomestatements.info
Category: Stock Reports